Tag: ImmunoOncology

Latest News

Vedanta Biosciences Announces Initiation of First-in-Patient Study of Immuno-Oncology Candidate VE800 In Combination with Bristol-Myers Squibb’s Opdivo® (Nivolumab)

Newsemia
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vedanta Biosciences Announces Initiation of First-in-Patient Study of Immuno-Oncology Candidate In Combination with Bristol-Myers Squibb’s Opdivo Source link...
Biology

Utilizing Immunosequencing in Immuno-Oncology and Immunotherapy Research, Upcoming Webinar Hosted by Xtalks

Newsemia
TORONTO (PRWEB) October 31, 2019 Join Patrick Raber, PhD, Manager, Research and Business Development at Adaptive Biotechnologies in a live webinar on Friday, November 15,...
Latest News

ESMO 2019: Forbius Demonstrates Target Engagement in Phase 1 Immuno-Oncology Clinical Trial with AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor

Newsemia
AUSTIN, Texas & MONTREAL–(BUSINESS WIRE)– #Austin–Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, today reported results from its non-clinical...
Latest News

Personalis, Inc. to Present at Advances in Immuno-Oncology Congress UK 2019

Newsemia
MENLO PARK, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/immuno19?src=hash" target="_blank"gt;#immuno19lt;/agt;–Personalis, Inc. to Present at Advances in Immuno-Oncology Congress UK 2019: Advancing Precision Oncology Biomarker Discovery with ImmunoID NeXT. Source...
Latest News

Celgene, following BMS buyout, forms two immuno-oncology partnerships

Newsemia
The company said Friday morning that it would partner with two companies, Kyn Therapeutics and Obsidian Therapeutics. Source link...
Pharma / Biotech

The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies.

Newsemia
Related Articles The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies. Eur J Cancer. 2018 Oct 03;103:259-266...
Latest News

Opdivo receives FDA approval as first Immuno-Oncology treatment option for small cell lung cancer

Newsemia
Bristol-Myers Squibb Company today announced that Opdivo received approval from the U.S. Food and Drug Administration as the first and only Immuno-Oncology treatment option for...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World